Immutep Ltd
- Biotech or pharma, therapeutic R&D
We are the global leader in the understanding of and in the development of therapeutics that modulate Lymphocyte Activation Gene-3 (“LAG-3”), a cell surface molecule which plays a vital role in regulating T cells, discovered by Dr. Frederic Triebel (Immutep CSO). The LAG-3 - MHC-II axis can be targeted at multiple focal points with effects seen in the innate and adaptive immune response simultaneously, which proves useful in treating oncology and autoimmune diseases.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}